174 results on '"Palmeri, Sergio"'
Search Results
2. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group
3. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401
4. Progression-free survival as an end-point in clinical trials of biotherapeutic agents
5. The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase I–II Study
6. Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study
7. Should cirrhosis change our attitude towards treating non-hepatic cancer?
8. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: Results of an Italian Multicenter, randomized, phase II study
9. Cytokine Gene Polymorphisms and Breast Cancer Susceptibility
10. Regulatory Cytokine Gene Polymorphisms and Risk of Colorectal Carcinoma
11. Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials
12. Flowcytometric analysis of multidrug-resistance-associated antigen (P-Glycoprotein) and DNA ploidy in human colon cancer
13. High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck
14. A phase II randomized trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine—cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC). A cooperative study of the IBCG (Italian Bladder Cancer Group)
15. Oxaliplatin plus folinic acid/fluorouracil i.v. bolus (OXAFAFU) vs irinotecan plus folinic acid/fluorouracil i.v. bolus (IRIFAFU) as first-line treatment of advanced colorectal carcinoma (ACC): Southern Italy Cooperative Oncology Group trial 0103
16. OXALIPLATIN PLUS LEUCOVORIN/FLUOROURACIL I.V. BOLUS (OXAFAFU) VERSUS IRINOTECAN PLUS LEUCOVORIN/FLUOROURACIL I.V. BOLUS (IRIFAFU) AS FIRST-LINE TREATMENT OF ADVANCED COLORECTAL CARCINOMA (ACC): SICOG 0103 RANDOMISED STUDY: 645
17. Paclitaxel, Gemcitabine and Cisplatin versus Gemcitabine-Cisplatin in Advanced Transitional Cell Carcinoma of the Urinary Tract (ATCC). A phase II randomised study of Southern Italy Cooperative Oncology Group (SICOG).
18. A PHASE I - II STUDY OF GEMCITABINE AND VINORELBINE AS SECOND LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER.
19. Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer
20. Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer
21. Progression-free survival as an end-point in clinical trials of biotherapeutic agents
22. Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients
23. 'Incidence of different KRAS mutation in non-small cell lung cancer (NSCLC) patients, TAILOR STUDY
24. 'Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet'
25. Weekly docetaxel (wDOC) for the treatment of metastatic breast cancer (MBC): A literature based meta-analysis
26. 'Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with early (E) breast cancer (BC)'
27. 'Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401'
28. 'Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (FA) and G-CSF for the treatment of gastroesophageal (GE) and gastric (G) cancer (C)'
29. 'Bevacizumab (Bev) with irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) i.v. every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): an observational study of the Southern Italy Cooperative Oncology Group (SICOG)'
30. 'Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC): results of an observational study'
31. 'Bevacizumab (BEV),irinotecan (IRI), folinic acid (FA) and fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): the Southern Italy Cooperative Oncology Group (SICOG) experience'
32. Weekly docetaxel in the treatment of metastatic breast cancer
33. Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey
34. 'Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials'
35. 'Serum HER-2/neu (s-HER2) levels evaluation in breast cancer (BC) patients (PTS)'
36. 'Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small cell lung cancer: a phase III randomized trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)'
37. 'Role of biomarkers in the regulatory process'
38. 'Capecitabine or folinic acid/fluorouracil i.v bolus plus eloxatin evaluation (COFFE trial) in metastatic colorectal carcinoma (MCRC): final results of the Southern Italy Cooperative Oncology Group (SICOG) 0401'
39. 'The European Medicines Agency (EMEA) guideline on oncology drug development'
40. 'OXXEL (Oxaliplatin plus Xeloda) versus OXAFAFU (Oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis'
41. 'Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site'
42. 'Long-term effect in outcomes of intensified primary chemotherapy in poor prognosis LABC T4 patients: results of a multicenter Italian study'
43. 'Intensified primary chemotherapy improved the outcome in poorer prognosis LABC T4 patients: results of a multicentric Italian study'
44. 'Impact of pathological response on survival in stage IIIB T4 LABC patients:long-term outcome of an Italian multicentric study'
45. 'OXXEL (oxaliplatin plus Xeloda) vs OXAFAFU (oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus) every 2 weeks in metastatic colorectal carcinoma (MCC): preliminary safety and activity analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial'
46. 'Preliminary results of G > GVIELC: a phase III trial of gemcitabine associated to vindesine or gemcitabine alone in elderly or poor performance patients with advanced non-small cell lung cancer (NSCLC)'
47. 'Cisplatin (P)- including triplets versus P-free doublets in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC): SICOG 0101 randomized trial'
48. 'Analysis of serum HER-2/neu levels (S-HER2) in breast cancer (BC) patients (pts)'
49. 'Results of a phase II study of a weekly regimen of cisplatin (CDDP),epirubicin (EPI), fluorouracil (5FU) and folinic acid (FA) with G-CSF in gastroesophageal (GE) and gastric (G) cancer'
50. Prognostic value of vascular endothelial growth factor (VEGF) and D-Dimer (DD) levels in cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.